Drug intelligence / Profile preview

TD-214

Development stage: Preclinical
Lead developer: TrippBio
Modality: Small Molecules
Administration: Oral

Overview

TD-214 is a small molecule prodrug developed by TrippBio, designed to optimize the delivery of PanCytoVir (probenecid) into the systemic circulation. Currently in preclinical development, TD-214 is being investigated for the treatment of respiratory viral infections, specifically Influenza and Respiratory Syncytial Virus (RSV). The drug functions by inhibiting organic anion transporters (OAT1 and OAT3), which are implicated in viral replication processes. Furthermore, TD-214 is designed to target ACE2, Pannexin 1 (PANX1), and the P2X7 receptor (P2X7R), mechanisms intended to block viral entry and modulate the host's inflammatory response to infection.

Targets

OAT1 (Organic anion transporter 1)PANX1 (Pannexin-1)SLC22A8 (Organic anion transporter 3)ACE2 (Angiotensin-converting enzyme 2)P2RX7 (P2X purinoceptor 7)

Beyond the preview

Go deeper on TD-214.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TD-214.

Explore the full profile